Here is the design of a clinical trial:

Official Title: Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study

Included conditions:
- COVID-19

Study Armgroups:
- {'label': 'Anluohuaxian combined with regular treatment group', 'type': 'EXPERIMENTAL', 'description': 'Anluohuaxian: 6g each time, twice a day', 'interventionNames': ['Drug: Anluohuaxian']}
- {'label': 'regular treatment group', 'type': 'NO_INTERVENTION'}

Interventions:
- {'type': 'DRUG', 'name': 'Anluohuaxian', 'description': '6g each time, twice a day', 'armGroupLabels': ['Anluohuaxian combined with regular treatment group']}

Primary Outcomes:
- {'measure': 'Changes in high-resolution computer tomography of the lung', 'description': 'Changes in ground-glass shadows, interstitial or air nodules found on high-resolution computer tomography', 'timeFrame': '3 months'}
- {'measure': 'Change in 6-minute walking distance', 'timeFrame': '3 months'}

Please estimate the sample size based on the assumption: 
Not explicitly stated in the provided paragraph.
Numbers to be randomised (sample size)
          750 patients are expected to be enrolled and the cases are allocated according to the ratio of 2 (Anluohuaxian combined with regular treatment group):1 (regular treatment group).